TY - JOUR T1 - Review: interferon and nucleoside/tide analogues reduce risk of hepato-cellular cancer in chronic hepatitis B JF - Evidence Based Medicine JO - Evid Based Med SP - 86 LP - 86 DO - 10.1136/ebm.14.3.86 VL - 14 IS - 3 A2 - , Y1 - 2009/06/01 UR - http://ebm.bmj.com/content/14/3/86.abstract N2 - Do interferon and nucleoside/tide analogues reduce risk of hepatocellular cancer (HCC) in patients with chronic hepatitis B virus (HBV) infection?Included studies compared interferon, pegylated interferon, or nucleoside/tide analogues (lamivudine, adefovir, entecavir, and telbuvidine) with no antiviral treatment (in any study type) or placebo (in randomised controlled trials [RCTs]) in patients with confirmed chronic HBV infection. Outcome was chronic hepatitis B-related HCC.Medline, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials and Database of Abstracts of Reviews of Effects, and International Pharmaceutical Abstracts (all to Nov or Dec 2007); abstracts from major international conferences in the past 10 years; and reference lists were searched for English-language RCTs, case–control studies, or cohort studies. 12 studies (n = 2742) … ER -